| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 55 | 2024 | 2431 | 8.060 |
Why?
|
| Carcinoma, Transitional Cell | 29 | 2024 | 999 | 4.970 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 11 | 2024 | 347 | 3.680 |
Why?
|
| Testicular Neoplasms | 14 | 2024 | 560 | 3.650 |
Why?
|
| Urothelium | 17 | 2024 | 264 | 2.790 |
Why?
|
| Ureteral Neoplasms | 16 | 2024 | 238 | 2.380 |
Why?
|
| Biomarkers, Tumor | 28 | 2024 | 10708 | 1.730 |
Why?
|
| Teratoma | 5 | 2023 | 248 | 1.620 |
Why?
|
| Kidney Neoplasms | 22 | 2024 | 3108 | 1.570 |
Why?
|
| Sarcoma | 5 | 2023 | 1839 | 1.550 |
Why?
|
| Adenocarcinoma | 15 | 2023 | 7914 | 1.510 |
Why?
|
| Urinary Bladder | 7 | 2021 | 593 | 1.470 |
Why?
|
| Oncogene Proteins, Fusion | 5 | 2017 | 797 | 1.380 |
Why?
|
| Ureter | 11 | 2023 | 219 | 1.310 |
Why?
|
| Carcinoma, Small Cell | 5 | 2018 | 427 | 1.280 |
Why?
|
| Neoplasm Invasiveness | 18 | 2024 | 4048 | 1.280 |
Why?
|
| Nephroureterectomy | 4 | 2024 | 48 | 1.200 |
Why?
|
| BCG Vaccine | 9 | 2024 | 428 | 1.180 |
Why?
|
| Immunohistochemistry | 21 | 2024 | 7655 | 1.150 |
Why?
|
| Cystectomy | 17 | 2024 | 635 | 1.130 |
Why?
|
| Carcinoma | 11 | 2022 | 2610 | 1.080 |
Why?
|
| Epithelioid Cells | 2 | 2024 | 45 | 1.030 |
Why?
|
| Prostatic Neoplasms | 16 | 2022 | 5866 | 1.010 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2024 | 23 | 0.970 |
Why?
|
| Mucous Membrane | 4 | 2024 | 263 | 0.950 |
Why?
|
| Urologic Neoplasms | 7 | 2024 | 202 | 0.940 |
Why?
|
| Disease Progression | 11 | 2024 | 6867 | 0.880 |
Why?
|
| Carcinoma, Neuroendocrine | 6 | 2023 | 743 | 0.860 |
Why?
|
| Hematuria | 2 | 2019 | 83 | 0.800 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2022 | 36 | 0.790 |
Why?
|
| Male | 84 | 2024 | 128315 | 0.750 |
Why?
|
| Neoplasm Recurrence, Local | 26 | 2023 | 10400 | 0.740 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2022 | 180 | 0.740 |
Why?
|
| GATA3 Transcription Factor | 3 | 2020 | 144 | 0.730 |
Why?
|
| Middle Aged | 64 | 2024 | 90352 | 0.720 |
Why?
|
| Gene Fusion | 3 | 2011 | 214 | 0.720 |
Why?
|
| Aged | 60 | 2024 | 73333 | 0.710 |
Why?
|
| Humans | 118 | 2024 | 270740 | 0.700 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2019 | 12 | 0.690 |
Why?
|
| Muscle, Smooth | 2 | 2020 | 251 | 0.690 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2024 | 1002 | 0.690 |
Why?
|
| Carcinogenesis | 3 | 2024 | 1033 | 0.660 |
Why?
|
| Wilms Tumor | 1 | 2022 | 301 | 0.650 |
Why?
|
| Urogenital System | 1 | 2019 | 60 | 0.650 |
Why?
|
| Uroplakin II | 2 | 2016 | 15 | 0.630 |
Why?
|
| Aged, 80 and over | 32 | 2024 | 30998 | 0.600 |
Why?
|
| Adult | 44 | 2024 | 82040 | 0.590 |
Why?
|
| Carcinoma, Papillary | 4 | 2021 | 566 | 0.590 |
Why?
|
| Seminoma | 6 | 2014 | 86 | 0.580 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2020 | 5593 | 0.570 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 42 | 0.570 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 1568 | 0.570 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2017 | 98 | 0.540 |
Why?
|
| Adjuvants, Immunologic | 7 | 2024 | 695 | 0.530 |
Why?
|
| Kidney Pelvis | 3 | 2017 | 114 | 0.530 |
Why?
|
| Neoplasm Grading | 10 | 2024 | 1823 | 0.510 |
Why?
|
| Uroplakin III | 1 | 2014 | 8 | 0.490 |
Why?
|
| Retrospective Studies | 34 | 2024 | 39890 | 0.490 |
Why?
|
| Biopsy | 8 | 2024 | 3484 | 0.460 |
Why?
|
| Urinary Tract | 3 | 2023 | 86 | 0.450 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2021 | 557 | 0.450 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2014 | 131 | 0.440 |
Why?
|
| Female | 51 | 2024 | 148940 | 0.440 |
Why?
|
| Prognosis | 26 | 2024 | 22505 | 0.430 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 428 | 0.420 |
Why?
|
| Carcinosarcoma | 1 | 2014 | 145 | 0.420 |
Why?
|
| Nephrectomy | 11 | 2014 | 798 | 0.400 |
Why?
|
| Orchiectomy | 4 | 2022 | 211 | 0.400 |
Why?
|
| Angiomyolipoma | 2 | 2010 | 30 | 0.390 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 213 | 0.390 |
Why?
|
| Mutation | 6 | 2024 | 15912 | 0.370 |
Why?
|
| Prostatectomy | 7 | 2022 | 1003 | 0.360 |
Why?
|
| Fatal Outcome | 4 | 2017 | 822 | 0.360 |
Why?
|
| Urogenital Neoplasms | 2 | 2024 | 115 | 0.340 |
Why?
|
| Young Adult | 15 | 2024 | 22251 | 0.340 |
Why?
|
| Hemangiosarcoma | 2 | 2010 | 238 | 0.340 |
Why?
|
| Administration, Intravesical | 4 | 2023 | 169 | 0.330 |
Why?
|
| RNA, Messenger | 3 | 2016 | 6390 | 0.330 |
Why?
|
| Carcinoma in Situ | 3 | 2016 | 489 | 0.330 |
Why?
|
| DNA Mutational Analysis | 3 | 2024 | 2357 | 0.310 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2024 | 2386 | 0.300 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2024 | 2313 | 0.300 |
Why?
|
| Cisplatin | 7 | 2023 | 2497 | 0.280 |
Why?
|
| Transcriptome | 1 | 2016 | 1963 | 0.280 |
Why?
|
| Carcinoma, Large Cell | 2 | 2021 | 98 | 0.280 |
Why?
|
| Tissue Array Analysis | 4 | 2016 | 757 | 0.280 |
Why?
|
| Survival Rate | 16 | 2017 | 12541 | 0.270 |
Why?
|
| Carcinoma, Verrucous | 1 | 2006 | 13 | 0.270 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 2665 | 0.270 |
Why?
|
| Neoplasm Staging | 18 | 2024 | 14012 | 0.270 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 2 | 2024 | 56 | 0.260 |
Why?
|
| Endodermal Sinus Tumor | 4 | 2013 | 50 | 0.260 |
Why?
|
| Treatment Outcome | 19 | 2024 | 33737 | 0.250 |
Why?
|
| Carcinoma, Ductal | 1 | 2006 | 144 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2024 | 9042 | 0.250 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 9039 | 0.240 |
Why?
|
| Gene Expression Profiling | 8 | 2020 | 5149 | 0.230 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2024 | 149 | 0.230 |
Why?
|
| Cytodiagnosis | 1 | 2024 | 201 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1388 | 0.220 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 4831 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2024 | 1563 | 0.210 |
Why?
|
| World Health Organization | 1 | 2024 | 327 | 0.210 |
Why?
|
| Organ Sparing Treatments | 1 | 2024 | 283 | 0.210 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 417 | 0.200 |
Why?
|
| Gene Rearrangement | 2 | 2019 | 813 | 0.200 |
Why?
|
| Folic Acid Antagonists | 1 | 2022 | 48 | 0.200 |
Why?
|
| Lymphatic Metastasis | 11 | 2014 | 4963 | 0.200 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 68 | 0.200 |
Why?
|
| Synaptophysin | 2 | 2011 | 83 | 0.190 |
Why?
|
| Transgender Persons | 1 | 2022 | 61 | 0.190 |
Why?
|
| Genomics | 3 | 2022 | 2835 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2024 | 3658 | 0.190 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 5162 | 0.190 |
Why?
|
| Telomerase | 1 | 2024 | 547 | 0.180 |
Why?
|
| Neoplasm Metastasis | 7 | 2017 | 5315 | 0.180 |
Why?
|
| Keratin-6 | 1 | 2020 | 40 | 0.180 |
Why?
|
| Keratin-5 | 1 | 2020 | 57 | 0.180 |
Why?
|
| Patient Selection | 3 | 2024 | 2025 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2018 | 6256 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2021 | 298 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 1240 | 0.180 |
Why?
|
| Pathology | 1 | 2021 | 102 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 4481 | 0.170 |
Why?
|
| Leiomyosarcoma | 3 | 2010 | 253 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2016 | 2090 | 0.170 |
Why?
|
| Databases, Genetic | 2 | 2020 | 757 | 0.170 |
Why?
|
| Adolescent | 8 | 2022 | 32767 | 0.170 |
Why?
|
| MicroRNAs | 3 | 2019 | 2887 | 0.160 |
Why?
|
| Cell Differentiation | 2 | 2024 | 4116 | 0.160 |
Why?
|
| Urology | 1 | 2020 | 140 | 0.160 |
Why?
|
| Immunotherapy | 4 | 2021 | 3557 | 0.160 |
Why?
|
| Carcinoma, Embryonal | 3 | 2013 | 31 | 0.160 |
Why?
|
| Androgen Antagonists | 2 | 2022 | 420 | 0.160 |
Why?
|
| Pathologists | 1 | 2019 | 101 | 0.150 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 66 | 0.150 |
Why?
|
| Lymph Node Excision | 6 | 2014 | 2062 | 0.150 |
Why?
|
| Mutagenesis | 1 | 2019 | 518 | 0.150 |
Why?
|
| Texas | 4 | 2018 | 6449 | 0.150 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 15218 | 0.150 |
Why?
|
| Whole Genome Sequencing | 2 | 2017 | 367 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 5231 | 0.140 |
Why?
|
| Clonal Evolution | 1 | 2019 | 250 | 0.140 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1049 | 0.140 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2016 | 32 | 0.140 |
Why?
|
| Disease-Free Survival | 11 | 2021 | 10265 | 0.140 |
Why?
|
| RNA-Binding Proteins | 2 | 2013 | 1017 | 0.140 |
Why?
|
| Muscle Neoplasms | 1 | 2017 | 108 | 0.140 |
Why?
|
| Keratin-14 | 1 | 2016 | 24 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2021 | 4000 | 0.130 |
Why?
|
| Nanomedicine | 1 | 2016 | 53 | 0.130 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2016 | 86 | 0.130 |
Why?
|
| Lung Neoplasms | 4 | 2014 | 12033 | 0.130 |
Why?
|
| Cell Transdifferentiation | 1 | 2017 | 114 | 0.130 |
Why?
|
| Multigene Family | 1 | 2017 | 469 | 0.130 |
Why?
|
| Aurora Kinase A | 1 | 2017 | 209 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 1402 | 0.130 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2017 | 347 | 0.130 |
Why?
|
| Survival Analysis | 4 | 2020 | 9292 | 0.120 |
Why?
|
| Gene Silencing | 1 | 2018 | 827 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 4 | 2012 | 1029 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 248 | 0.120 |
Why?
|
| PPAR gamma | 1 | 2016 | 225 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 680 | 0.120 |
Why?
|
| Urethral Neoplasms | 1 | 2014 | 62 | 0.110 |
Why?
|
| Plasmids | 1 | 2016 | 936 | 0.110 |
Why?
|
| Liposomes | 1 | 2016 | 704 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 2651 | 0.110 |
Why?
|
| Virus Integration | 1 | 2014 | 73 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 4821 | 0.110 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2013 | 14 | 0.110 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 3339 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 3035 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 5101 | 0.110 |
Why?
|
| DNA Helicases | 1 | 2016 | 450 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 4960 | 0.110 |
Why?
|
| Retroperitoneal Space | 1 | 2013 | 156 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 875 | 0.110 |
Why?
|
| Hyperplasia | 2 | 2022 | 564 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2019 | 1320 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1335 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 5776 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 637 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1012 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1302 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 841 | 0.100 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2014 | 81 | 0.100 |
Why?
|
| Chromogranins | 1 | 2011 | 86 | 0.100 |
Why?
|
| Acid Phosphatase | 1 | 2011 | 56 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2013 | 354 | 0.100 |
Why?
|
| Oncogene Fusion | 1 | 2011 | 62 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 1286 | 0.100 |
Why?
|
| Phenotype | 2 | 2020 | 6509 | 0.090 |
Why?
|
| Chromogranin A | 1 | 2011 | 67 | 0.090 |
Why?
|
| Kidney | 3 | 2021 | 2121 | 0.090 |
Why?
|
| Cell Death | 1 | 2013 | 685 | 0.090 |
Why?
|
| DNA Methylation | 2 | 2019 | 2765 | 0.090 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2011 | 109 | 0.090 |
Why?
|
| Keratins | 1 | 2011 | 340 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2020 | 6224 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 190 | 0.090 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 656 | 0.090 |
Why?
|
| Pyrazines | 1 | 2013 | 510 | 0.090 |
Why?
|
| Viscera | 1 | 2010 | 92 | 0.090 |
Why?
|
| Lymph Nodes | 2 | 2013 | 3077 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 3844 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 550 | 0.090 |
Why?
|
| Biopsy, Needle | 2 | 2021 | 1379 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 690 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2014 | 902 | 0.080 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 275 | 0.080 |
Why?
|
| ErbB Receptors | 2 | 2009 | 2375 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3409 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2016 | 5438 | 0.080 |
Why?
|
| Leiomyoma | 1 | 2010 | 161 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1054 | 0.080 |
Why?
|
| Chromatin | 1 | 2014 | 1046 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 2197 | 0.080 |
Why?
|
| Time Factors | 3 | 2017 | 13006 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1341 | 0.080 |
Why?
|
| Cell Nucleus | 3 | 2010 | 1712 | 0.080 |
Why?
|
| Image-Guided Biopsy | 2 | 2021 | 336 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1260 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2014 | 2137 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 1903 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2010 | 282 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 689 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2098 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 1553 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2014 | 1149 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5408 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 1710 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2399 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2069 | 0.070 |
Why?
|
| Condylomata Acuminata | 1 | 2006 | 32 | 0.070 |
Why?
|
| Health Surveys | 2 | 2020 | 400 | 0.070 |
Why?
|
| Child | 4 | 2017 | 30559 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 427 | 0.070 |
Why?
|
| Quinazolines | 1 | 2011 | 956 | 0.060 |
Why?
|
| Animals | 5 | 2024 | 61956 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 16689 | 0.060 |
Why?
|
| Prostate | 1 | 2010 | 1089 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2019 | 3438 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1049 | 0.060 |
Why?
|
| Ureteroscopy | 1 | 2024 | 52 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2010 | 1624 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 1075 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 7783 | 0.060 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2024 | 89 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2024 | 67 | 0.060 |
Why?
|
| Necrosis | 3 | 2010 | 595 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7381 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2021 | 12103 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2012 | 2123 | 0.060 |
Why?
|
| Mitosis | 3 | 2010 | 681 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5595 | 0.050 |
Why?
|
| Laparoscopy | 2 | 2009 | 1302 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2006 | 636 | 0.050 |
Why?
|
| Risk Factors | 5 | 2021 | 17888 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2024 | 2828 | 0.050 |
Why?
|
| Gender Identity | 1 | 2022 | 79 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 116 | 0.050 |
Why?
|
| Piperazines | 1 | 2011 | 2145 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 3917 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 271 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2024 | 418 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 285 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 2617 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2024 | 600 | 0.040 |
Why?
|
| alpha-Fetoproteins | 2 | 2013 | 255 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2021 | 6764 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 1094 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2013 | 17061 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2021 | 427 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 772 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 592 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 334 | 0.040 |
Why?
|
| Mice | 3 | 2024 | 35600 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2023 | 1389 | 0.040 |
Why?
|
| Sequence Analysis, Protein | 1 | 2017 | 80 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 323 | 0.040 |
Why?
|
| Snail Family Transcription Factors | 1 | 2017 | 120 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 13414 | 0.030 |
Why?
|
| Receptors, Transferrin | 1 | 2016 | 41 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2017 | 220 | 0.030 |
Why?
|
| Vinblastine | 1 | 2017 | 462 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 678 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 14849 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1032 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 1106 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2016 | 61 | 0.030 |
Why?
|
| United States | 4 | 2018 | 15861 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 339 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1089 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 2250 | 0.030 |
Why?
|
| Transgenes | 1 | 2016 | 576 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 7895 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1097 | 0.030 |
Why?
|
| Methotrexate | 1 | 2017 | 1025 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 676 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 4328 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 375 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 126 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2013 | 125 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 218 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 804 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 7100 | 0.030 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 14617 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 709 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 396 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2013 | 367 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 507 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 6177 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1109 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2013 | 895 | 0.020 |
Why?
|
| Bortezomib | 1 | 2013 | 549 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2024 | 3669 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2017 | 1567 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 453 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2013 | 848 | 0.020 |
Why?
|
| DNA Primers | 1 | 2013 | 1496 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 1291 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 5257 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 1888 | 0.020 |
Why?
|
| Choriocarcinoma | 1 | 2010 | 49 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2010 | 151 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 1076 | 0.020 |
Why?
|
| Peritoneum | 1 | 2011 | 151 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2010 | 105 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2017 | 3145 | 0.020 |
Why?
|
| Chile | 1 | 2009 | 68 | 0.020 |
Why?
|
| Giant Cells | 1 | 2010 | 73 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2010 | 306 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2010 | 279 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1199 | 0.020 |
Why?
|
| Japan | 1 | 2009 | 241 | 0.020 |
Why?
|
| Ki-1 Antigen | 1 | 2010 | 186 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 512 | 0.020 |
Why?
|
| Cell Movement | 1 | 2017 | 2472 | 0.020 |
Why?
|
| North America | 1 | 2009 | 338 | 0.020 |
Why?
|
| Spermatozoa | 1 | 2011 | 292 | 0.020 |
Why?
|
| Urologic Surgical Procedures | 1 | 2009 | 93 | 0.020 |
Why?
|
| Research Design | 1 | 2016 | 1569 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 1340 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1716 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 484 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 254 | 0.020 |
Why?
|
| Europe | 1 | 2009 | 658 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 1754 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1499 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 3597 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2007 | 205 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1826 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 2010 | 342 | 0.020 |
Why?
|
| Physicians | 1 | 2014 | 854 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 2027 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3530 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2184 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7238 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 9470 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2453 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 1894 | 0.010 |
Why?
|
| Proteins | 1 | 2010 | 2043 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2007 | 1857 | 0.010 |
Why?
|
| Neoplasms | 1 | 2021 | 15927 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 13999 | 0.010 |
Why?
|